Artificial Nanoscale Cholesterol Carrier Targets Brain Tumors

Low-density lipoprotein, better known as LDL, is one of the chief villains involved in the development of coronary artery disease. But new research results suggest that for cancer patients with glioblastoma multiforme (GBM), the most common malignant brain tumor in adults, synthetic LDL-like nanoparticles could prove to be the vehicle of choice for delivering potent anticancer drugs to tumor cells while sparing healthy neighboring cells.

Writing in the International Journal of Pharmaceutics, a team of investigators led by Trudy Forte, Ph.D., at the Children’s Hospital of Oakland Research Institute, describes its development of a multicomponent nanoparticle that targets a cell-surface LDL receptor that is overproduced by glioblastoma cells, as well as by other tumor cells. Healthy brain cells, in contrast, have relatively low levels of the LDL receptor in their cell membranes.

To construct their nanoparticles, the investigators started with a mix of lipids, cholesterol, and a small, synthetic protein that contains two functional regions. One region acts as an LDL receptor binding region and the other as a lipid binding region that helps hold the nanoparticle together. Initial experiments confirmed that the resulting 10-nanometer diameter particles bound efficiently to the surface of GBM cells growing in culture and that they could prevent this binding using a compound known to inhibit the interaction of natural LDL particles with their receptor.

Using a fluorescent dye as a model drug, the researchers then showed that glioblastoma cells took up the synthetic nanoparticles. The investigators note that the small size of these synthetic nanoparticles make them suitable for delivery into the brain using a technique known as convection enhanced delivery. Natural LDL particles do not cross the blood-brain barrier.

This work is detailed in a paper titled, “Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme.” Investigators from the Lawrence Berkeley National Laboratory and the University of California, Berkeley, also participated in this study. This paper was published online in advance of print publication. An abstract of this paper is available at the journal’s website.

Source: National Cancer Institute

Related stories:

High cholesterol levels drop naturally in children on high-fat anti-seizure diet, study show
Elevated cholesterol levels return to normal or near normal levels over time in four out of 10 children with uncontrollable epilepsy treated with the high-fat ketogenic diet, according to results of a Johns Hopkins Children's Center study reported in the Journal of Child Neurology.
Unexpected finding of molecule's dual role in mice may open new avenue to cholesterol reduction
Researchers have discovered an unknown regulator of fat and cholesterol production in the liver of mice, a significant finding that could lead to new therapies for lowering unhealthy blood levels of cholesterol and fats.
Researchers find drugs being tested for Alzheimer's disease work in unexpected and beneficial ways
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
New blood test reveals risk for metabolic syndrome
University of Minnesota researchers have discovered that people with high oxidation levels of the low-density lipoprotein (LDL) particle that carries cholesterol throughout the blood are much more likely to develop metabolic syndrome – which can lead to a considerably increased risk of developing heart disease.
Oxidative stress may predict later lung trouble in young adults
Markers of oxidative stress may predict future lung trouble, according to new research to be presented at the American Thoracic Society’s 2008 International Conference in Toronto on Wednesday, May 21.
Pistachios reduce inflammation, cardiovascular disease factors
A Penn State-led study shows that snacking on pistachios has proved to have a positive impact on improving cardiovascular health by significantly reducing inflammation in the body, a prominent cardiovascular disease risk factor.
Mixed results for weight loss drug on slowing progression of coronary disease
The anti-obesity medication rimonabant showed mixed results in slowing progression of coronary artery disease in patients with abdominal obesity and pre-existing coronary disease, according to a new study in the April 2 issue of JAMA. The study is being released early online April 1 to coincide with its presentation at the annual conference of the American College of Cardiology.
Lipoic acid could reduce atherosclerosis, weight gain
A new study done with mice has discovered that supplements of lipoic acid can inhibit formation of arterial lesions, lower triglycerides, and reduce blood vessel inflammation and weight gain – all key issues for addressing cardiovascular disease.

News discussion:

Nanotechnology news